Since the debut of its first cGMP manufacturing facility in 2015, TriLink has reliably delivered GMP batches to its customers. Purpose-built for mRNA drug substance manufacturing, the new cGMP facility will contribute to the development and manufacturing of vital mRNA vaccines and therapeutics. The new facility is slated to welcome customers in early 2024.
The new 32,000 ft2 cGMP facility has been designed by mRNA and regulatory experts to streamline late-phase clinical mRNA drug substance manufacturing. Drug development programs will be supported by ISO 7 cleanrooms, increased mRNA capacity (1g to > 50g per batch), and in-house analytical services.
Leverage TriLink's 25-plus years of mRNA and manufacturing experience and expertise with access to in-house analytical services and expert counsel for process optimization, scale-up, validation, and qualification.